Compare AVXL & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | NCV |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.7M | 358.8M |
| IPO Year | 2013 | N/A |
| Metric | AVXL | NCV |
|---|---|---|
| Price | $4.49 | $16.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 101.2K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $11.51 |
| 52 Week High | $13.99 | $16.70 |
| Indicator | AVXL | NCV |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 58.92 |
| Support Level | $3.60 | $15.55 |
| Resistance Level | $4.88 | $16.70 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 78.01 | 72.33 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.